A FINANCIAL PERSPECTIVE ON THE PHARMACEUTICAL INDUSTRY

被引:0
|
作者
Kahraman, Yunus Emre [1 ]
Caliskan, Yilmaz [2 ]
机构
[1] Osmaniye Korkut Ata Univ, Hlth Serv Vocat Sch, Dept Pharm Serv, TR-80000 Osmaniye, Turkiye
[2] Mugla Prov Directorate Environm Urbanizat & Climat, Fethiye Natl Estate Directorate, TR-48300 Mugla, Turkiye
来源
关键词
Pharmaceuticals; Public Health; Finance; Financial Markets; MEDICINES; INCOME;
D O I
10.56782/pps.180
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
As a result of the epidemics in the world in recent years the importance of the health sector has once again emerged and countries have started to invest more in the health sector. In addition to developed countries, underdeveloped and developing countries are investing more in the health sector and technology and governments are trying to control increasing health expenditures. One of the important and dynamic sub-sectors of the health sector is the pharmaceutical sector. States and international companies are investing more in the pharmaceutical sector in order to combat the epidemics in recent years and are conducting more R&D studies by utilizing the developing technology. In this study in the light of the data published by the OECD, it is examined whether there is a similar relationship between the change in the share of health expenditures in the GNP (Gross National Product) of OECD countries between 2010 and 2022 and the change in the size of the pharmaceutical sector in OECD countries. The change in the size of the pharmaceutical sector and the change in the share of health expenditures in GNP have not yielded similar results in each OECD country. It is thought that different factors such as demographic characteristics, geographical location and economic conditions of countries should be taken into consideration when evaluating the relationship between these two variables.
引用
收藏
页码:23 / 31
页数:9
相关论文
共 50 条
  • [1] A Rasch Perspective on Firm Financial Performance in the Pharmaceutical Industry
    Jambulingam, Thani
    Schellhorn, Carolin
    Sharma, Rajneesh
    [J]. CELEBRATING AMERICA'S PASTIMES: BASEBALL, HOT DOGS, APPLE PIE AND MARKETING?, 2016, : 469 - 469
  • [2] Pharmaceutical industry financial performance
    Goodman, Michael
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (12) : 927 - 928
  • [3] Pharmaceutical industry financial performance
    Michael Goodman
    [J]. Nature Reviews Drug Discovery, 2009, 8 : 927 - 928
  • [4] Hormesis - A pharmaceutical industry perspective
    Olson, HM
    Kadyszewski, E
    Beierschmitt, W
    [J]. CRITICAL REVIEWS IN TOXICOLOGY, 2001, 31 (4-5) : 659 - 661
  • [5] Financial risk of the Biotech Industry versus the Pharmaceutical Industry
    Joseph Golec
    John A. Vernon
    [J]. Applied Health Economics and Health Policy, 2009, 7 (3) : 155 - 165
  • [6] Financial Risk of the Biotech Industry versus the Pharmaceutical Industry
    Golec, Joseph
    Vernon, John
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2009, 7 (03) : 155 - 165
  • [7] A PERSPECTIVE ON FINANCIAL INDUSTRY NETWORKING
    WEINSTEIN, SB
    [J]. JOURNAL OF TELECOMMUNICATION NETWORKS, 1982, 1 (04): : 317 - 332
  • [8] The Trouble with Hydrates - A Pharmaceutical Industry Perspective
    Nagel, Norbert
    [J]. ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2009, 65 : S102 - S102
  • [9] Epidemiology in the pharmaceutical Industry: a Canadian perspective
    Rawson, Nigel S. B.
    De Souza, Leanne R.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 (10) : 758 - 762
  • [10] Financial Situation of Listed Companies in Pharmaceutical Industry
    Yan, Haokun
    Xu, Ting
    [J]. PROCEEDINGS OF THE FIFTH SYMPOSIUM OF RISK ANALYSIS AND RISK MANAGEMENT IN WESTERN CHINA (WRARM 2017), 2017, 152 : 110 - 114